1[1]Ferrannini E.Insulin resistance versus insulin deficiency in noninsulin-dependent diabetes mellitus:problems and prospects.Endocrine Reviews,1998,19:477-490
2[2]Meigs JB,Wilson P.WF,Nathan DM,et al.Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham offspring Studies.Diabetes,2003,8:2160-2167
4[4]Arner P.Free fatty acids-do they play a central role in type 2diabetes.Diabetes,Obesity & Metabolism,2001,3 (Suppl.1):S11-S19
5[5]Banerji M,Lebovitz HE & Dugbartey M.Rosiglitazone selectively increases subcutaneous but not visceral adipose tissue mass in type 2 diabetes mellitus.Diabetes,2001,50 (Suppl 2):A90
6[6]Smith S,Boam DS,Bretherton-Watt D,et al.Rosiglitazone increases pancreatic islet area,density and insulin content,but not insulin gene expression.Diabetes,1998,47 (Suppl.1):A18
7[7]Patel J,Weston WM & Hemyari P.Rosiglitazone (RSG) decreases insulin resistance (IR) and improves beta-cell function (BCF) in patients with type 2 diabetes mellitus.Endocrine Society 81st Annual Meeting:Program and Abstracts,1999,470:Abstract P3-P153
8[8]Aronoff S,Rosenblantt S,Braithwaite S,et al.Pioglitazone hydrochloride monotherapy improves glycemie control in the treatment of patients with type 2 diabetes:a 6-month randomized placebo-controlled dose -response study.The Pioglitazone 001Study Grope.Diabetes Care,2000,23:1605-1611
10[10]Raskin P,Dole JF & Rappaport EB.Rosiglitazone improves glycemic control in poorly controlled,insulin-treatd type 2 diabetes (T2D).Diabetes,1999,48 (Suppl.1):A94
二级参考文献7
1Matthaei S,Stumvoll M,Kellerer M,et al.Pathophysiology and pharmacological treatment of insulin resistance[J].Endocrine Reviews,2000,21(6):585-618.
2Schernthaner G,Matthews DR,Charbonnel B,et al.Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus:a double-blind,randomized trial[J].J Clin Endocrinol Metab,2004,89(12):6 068-6 076.
3Pavo I,Jermendy G,Varkonyi TT,et al.Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes[J].J Clin Endocrinol Metab,2003,88(4):1 637-1 645.
4Mimura K,Umeda F,Hiramatsu S,et al.Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes[J].Diabet Med,1994,11(7):685-691.
5Fullert S,Schneider F,Haak E,et al.Effects of pioglitazone in nondiabetic patients with arterial hypertension:a double-blind, placebo-controlled study[J].J Clin Endocrinol Metab,2002,87(12):5 503-5 506.
6Aronoff S,Rosenblatt S,Braithwaite S,et al.Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes:a 62-month randomized placebo-controlled dose-response study.The Pioglitazone 001 Study Group[J].Diabetes Care,2000,23(11):1 605-1 611.
7Kelly IE,Han TS,Walsh K,et al.Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes[J].Diabetes Care,1999,22(2):288-293.
